Oritavancin for Staphylococcus Aureus Infections in Opioid Users
NCT03761953
·
clinicaltrials.gov ↗
PHASE4
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
COVID 19 pandemic
Conditions
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Endocarditis
Interventions
DRUG:
Oritavancin Injection
Sponsor
University of Pennsylvania